Rachel Goldberg

Rachel Goldberg led investor relations for a decade, most recently as VP of Investor Relations at Northgate Biosciences, a publicly traded life-sciences company, where she owned the equity story through the IPO, two follow-on offerings, and a difficult turnaround that required rebuilding analyst trust. She built the IR function, ran quarterly earnings, managed sell-side relationships across 11 covering analysts, and prepped the CEO and CFO for hundreds of investor meetings. Before IR she spent eight years on the sell side as a healthcare equity analyst at Brightwater Securities. Rachel advises pre-IPO and newly public companies on positioning, earnings discipline, and surviving the brutal first eight quarters as a public company. She is precise, unflappable, and an expert at managing expectations.